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ABSTRACT 
Objectives: To compare the immunogenicities and reacto- 
genicities of bicomponent (B) (pertussis toxoid, filamentous 
hemagglutinin) and tricomponent (T) (pertussis toxoid, fila- 
mentous hemagglutinin, pertactin) acellular pertussis vaccines 
when coadministered with diphtheria and tetanus toxoids in 
primary (3, 4, and 5 mo) and booster (15-I 9 mo) vaccinations. 
Design and Methods: A randomized, double-blind study involv- 
ing 175 children aged 12 to 18 weeks. Reactogenicity was 
based on diary cards, immunogenicity assessed by ELISA mea- 
surements of serum IgG antibodies. 
Results: There were no clinically relevant differences in local 
(B = 34.5; T = 31.3%) and general (B = 43.9; T = 41.8%) reac- 
togenicities between the two vaccines during the primary vac- 
cinations. Booster doses caused significantly more adverse 
reactions than primary vaccination, but local (B = 77.6; 
T = 66.2%) and general (B = 64.2; T = 60.8%) reaction rates 
remained similar for the two vaccines. Both vaccines had 
almost identical immunogenicities with respect to the corre- 
sponding antigens and elicited seropositive antibody titers in 
100% of the recipients of vaccines against diphtheria, tetanus, 
and the respective pertussis antigens 1 month after primary 
and booster vaccinations. 
Conclusions: The tricomponent vaccine was no more reacto- 
genie than the bicomponent vaccine and at least as immuno- 
genic for the respective antigens. Because tricomponent 
vaccine reliably induces antibodies to an additional antigen 
involved in immunoprotection, it may be preferable for use in 
primary as well as booster vaccination. 
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Pertussis attacks 60 million people annually, causing an 
estimated 600,000 deaths worldwide.‘a2 The pertussis- 
related mortality rate in children less than 3 years old 
is about 0. l%, and significant long-term sequelae are 
observed in 1% of cases.3 In a population with a low 
immunization rate, 4% to 6% of children develop clinical 
pertussis each year.* About 10% of the patients are infants 
less than 1 year old, and 6% are younger than 6 months. 
Incidence increases with age, reaching a maximum of 
15% to 20% in 4- and 5-year-old children.* In countries 
with a high degree of immunization such as the United 
States, 50% of all cases of pertussis occur during the first 
year of life, and only about 10% during adulthood.5 
Longitudinal studies performed in Great Britain, 
Sweden, Japan, and the former German Democratic 
Republic show that the incidence of clinical whooping 
cough in young children depends mainly on the rate of 
vaccination of the population.‘-’ Broad immunization cov- 
erage in young children declined in many countries fol- 
lowing adverse reactions associated with the highly 
reactogenic whole-cell pertussis vaccines and was asso- 
ciated with increasing incidences of clinical disease.5-7,10a11 
The lack of public acceptance of the whole-cell vaccines 
prompted the development of partially purified acellu- 
lar pertussis vaccines, originally in Japan.’ More recent 
research has identified four bacterial components with 
the ability to elicit potentially protective immune 
responses: pertussis toxoid (FI), filamentous hemagglu- 
tinin @HA), a 69 kDa outer membrane antigen (pertactin) 
and agglutinogens. Recently developed acellular mono-, 
bi-, and tricomponent vaccines composed of different 
combinations of these antigens have been applied for the 
booster immunization of 15- to 24-month-old children,i2-l7 
and also, to a lesser extent, for the primary immunization 
of infants.13~18~19 However, no study has been published 
that assesses the reactogenicity and immunogenic&y of 
an acellular pertussis vaccine in a cohort of children 
receiving a complete primary vaccination course followed 
by a booster vaccination with the same vaccine at an 
appropriate later time. 
This report presents the results of a prospective, 
randomized, double-blind study in German infants aged 
12 to 18 weeks who were vaccinated with either a 
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bicomponent or a tricomponent acellular pertussis vac- 
cine in a primary series and then with a booster dose of 
the same vaccine at 15 to 19 months of age. The purpose 
of the study was to ensure that the inclusion of a third 
antigen in an acellular pertussis vaccine did not interfere 
with the immune response, while also ensuring that the 
additional antigen did not increase the reactogenicity of 
the vaccine. 
SUBJECTS AND METHODS 
Study Design 
The study was a randomized, double-blind trial. Healthy 
children aged 12 to 18 weeks not previously immunized 
against Bordetella pertussis, diphtheria, or tetanus were 
eligible for the study, provided that they had no clinical 
history of whooping cough or of progressive neurologic 
disease, there was no allergy present, they had no chronic 
disease necessitating chronic medication, and they did 
not participate in another clinical trial or vaccination study. 
Those children who completed the primary vaccination 
course were eligible for the booster study, subject to the 
same original exclusion criteria, and provided that they 
had not experienced any severe adverse reactions during 
the primary course. Upon enrollment, children were ran- 
domly assigned either to group B (bicomponent) to 
receive three doses of SmithKline Beecham’s (Rixensart, 
Belgium) bicomponent acellular diphtheria-tetanus-per- 
tussis @Tap) vaccine, or to group T (tricomponent) to 
receive three doses of the same manufacturer’s tricom- 
ponent acellular DTaP vaccine (InfanrixTM). Primary doses 
were administered 4 weeks apart, the booster vaccina- 
tion being administered when the child was between 14 
and 20 months of age (i.e., 9 to 15 months after the third 
vaccine dose). Haemophilus influenzae type b and oral 
polio vaccinations were administered during the course 
of the trial according to the German vaccination schedule. 
The study was conducted in accordance with the 
Declaration of Helsinki as amended in Hong Kong (1989) 
and the German Drug Act, the study protocol having 
been approved by the responsible Medical Ethics Com- 
mittee. Parents were informed orally and by a detailed 
information sheet of possible risks and advantages of par- 
ticipating in a randomized vaccination study, before they 
provided written consent. 
Children had a full clinical examination and the rec- 
tal temperature was recorded prior to each vaccination. 
After injection of 0.5 mL of the respective vaccine into 
the right thigh, the infant was closely observed for 30 
minutes. To assess the reactogenicity of the vaccine, the 
caretakers of each vaccinated child received a diary card 
to be fflled out in the evening on the day of the vacci- 
nation as well as during the 7 following days. The diary 
cards were collected at the next vaccination visit, and 
data were entered into a standardized reactogenicity doc- 
umentation form by the study pediatrician. 
The diary cards solicited comments with respect to 
local redness and swelling (the diameter of which was 
measured), pain on digital pressure at the injection site, 
fever (rectal temperature 38°C or higher, with exact tem- 
peratures recorded), vomiting, diarrhea, drinking or eat- 
ing less than usual, sleep disturbances (sleeping more or 
less than usual), and unusual crying for periods of more 
than 1 hour. All local reactions were graded according to 
severity, (i.e., as mild, moderate, or severe). In addition, 
comments relating to any kind of unsolicited reaction 
occurring during a period of 8 days were encouraged. 
Vaccines 
The vaccines were provided by SmithKline Beecham as 
coded mono-dose 0.5 mL vials; neither the pediatrician 
nor the caretakers were able to distinguish between vials 
of the two vaccine types. The bicomponent DTaP vaccine 
contained 25 pg PT and 25 pg FHA antigen as well as at 
least 30 IU of diphtheria toxoid and 40 IU of tetanus tox- 
oid adsorbed onto 0.5 mg of aluminum (as aluminum 
hydroxide) (lots DTAP OOlA2 and 006~2 for primary and 
booster, respectively). In addition to these antigens, the 
tricomponent vaccine contained 8 yg pertactin (lots 
DTAP lOlA2 and 102A2, respectively). 
Assessment of Immunogenicity 
To determine individual antibody responses, a venous 
blood sample (2 0.5 mL) was obtained immediately 
before the first dose and 1 month after the third dose of 
the primary series, and immediately before and 1 month 
after the booster dose. Sera were stored at -20°C until 
assay of the IgG antibodies against the vaccine antigens. 
Anti-PT, anti-FHA, and antipertactin IgG antibodies were 
measured using enzyme-linked immunosorbent assays 
@LISA), with the results expressed in ELISA units (EL.U) 
per milliliter.20,21 The cutoff limit was set at 5 EL.U/mL, 
a value 3 to 4 times higher than the limit of sensitivity 
of the assay. Samples containing less than 5 EL.U/mL were 
considered as negative. 
A vaccine-induced immune response after a full pri- 
mary immunization course was defined for initially 
seronegative children as an antibody titer of 5 EL.U/mL or 
higher. For initially seropositive children, because of the 
presence of maternally acquired antibodies, a postvacci- 
nation antibody titer at least equal to the antibody titer at 
the beginning of the study was considered as a positive 
response, thereby taking into account the natural kinet- 
ics of maternal anti-B.pertussis antibodies (i.e., a decrease 
of approximately 50% during a period of 4 weeks). A 
booster response was defined as a doubling of the pre- 
booster level for seropositive children and an antibody 
titer of 5 EL.U/rnL or higher for seronegative children. 
Antidiphtheria toxoid and antitetanus toxoid IgG anti- 
bodies also were measured using ELISA methods,Z2,23 with 
results reported in International Units (Iu) per milliliter. 
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Although it is generally accepted that protection occurs 
at titers of 0.01 IU/mL or higher for these antibodies, a 
conservative cutoff value of 0.1 IU/mL was routinely 
applied to ensure a good correlation between the ELISA 
and values obtained using in vivo neutralization tests.23,24 
Statistical Analysis 
The chi-square test and two-way analysis of variance 
(ANOVA) were used to compare the demographic char- 
acteristics of each group. The &i-square test was applied 
to the incidences of solicited reactions, and the prevac- 
cination status with respect to pertussis antibodies. 
Fisher’s exact test was applied to compare the response 
to pertussis components. A probability of P < 0.05 was 
considered to be of statistical significance. 
RESULTS 
Demographics 
The demographics of the original study population are 
shown in Table 1. Four of the original subjects were 
excluded from the reactogenicity analysis of the primary 
series: three had received a vaccine not specified in the 
protocol, and no diary cards were returned for another. 
A further 17 subjects were excluded from the immuno- 
genic&y analyses for other reasons: being outside of the 
protocol age range (n = 7) not following the vaccina- 
tion schedule (n = l), missing blood samples (n = 3) 
incoherence in the results (n = l), or because the sub- 
jects were exposed to clinical cases of pertussis during 
the trial (n = 5). 
Although there were 157 subjects from the original 
study population available for the booster study, 14 were 
excluded from the reactogenicity analyses because they 
received other vaccinations during the clinical trial 
period. Of the remaining 143 subjects, 40 could not be 
included in the immunogenicity analyses because of the 
lack or insufficient quantity of blood samples (n = 32) 
being outside of the specified age range (n = 2) or hav- 
ing irregular blood sampling schedules (n = 6). 
Reactogenicity 
In accordance with the recommendations of Pichichero 
et a1,25 only the adverse reactions occurring within 48 
Table 1. Demographic Characteristics of the Study Population at 
Admission to Primary and Booster Studies 
Study Groups 
Primary Series 
7Womponent* Bicomponent* 
n M:F+ Mean n M:Ft Mean 
Age Age 
Enrollment (n = 175) 88 1.00 14.3 wk 87 0.91 14.6wk 
Reactogenicity (n = 171) 86 0.95 14.3 wk 85 0.89 14.6 wk 
lmmunogenicity (n = 154) 80 1 .OO 14.3 wk 74 0.85 14.4 wk 
Booster Dose 
Enrollment (n = 157) 81 0.98 15.7 mo 76 0.90 16.1 mo 
Reactogenicity (n = 143) 75 0.97 15.6 mo 68 1 .OO 15.9 mo 
lmmunogenicity (n = 103) 48 1 .OO 15.6 mo 55 1 .I2 15.9 mo 
*There were no statistically significant differences between the two groups. 
+Male:female ratio. 
hours of the vaccination are detailed as being relevant to 
the comparison of the two vaccines. However, when symp- 
toms occurring between 48 hours and 8 days after injec- 
tion were taken into account, the pattern of adverse 
reactions was essentially unchanged (data not presented). 
Whereas the frequency of local adverse reactions did not 
change at all, there were small, nonsignit?cant increases in 
the incidences of fever, sleep disturbances, and eating 
and/or drinking less than usual, which affected both vac- 
cination groups in a similar manner. In the majority of cases, 
adverse reactions did not necessitate any specific medica- 
tion, such as antipyretics or analgesics administration. 
The incidences of local and general adverse reactions 
that occurred during the first 48 hours after each vac- 
cine dose are detailed in Tables 2 and 3, respectively 
Similar frequencies of all types of adverse reactions were 
observed for the bicomponent and tricomponent DTaP 
vaccines, independent of the vaccine dose, with the 
exception that redness occurred slightly more often in 
group B than in group T (P = 0.03) after the second dose 
(see Table 2). 
There was a trend for local swelling and redness to 
increase with each subsequent dose during the primary 
series, irrespective of the type of vaccine administered, 
but the frequency of local pain did not change between 
the first and third vaccine doses (see Table 2). However, 
booster doses were associated with larger increases in 
reporting of swelling and redness, and a significantly 
increased incidence of pain (P c 0.001) when compared 
with the third vaccine dose (see Table 2). The booster 
Symptom 
Table 2. lncidences of Local Symptoms in the First 48 Hours following Vaccination* 
Vaccine Dose 
I /I /// Booster 
(n =T86) (n zB85, (n =T86) (n =“e5) (n =T84j (n =B85) (n =B67) 
Pain 3.5 1.2 3.5 2.4 2.4 2.4 24.3 
Swelling 2.3 3.5 14.0 18.8 25.0 18.8 41.9 
Redness 18.6 16.5 27.9 44.7+ 38.1 32.9 60.8 
*As a percentage of total number of report sheets returned for each dose administered: Eignificantly different from tricomponent (P = 0.03). 
T = tricomponent group; B = bicomponent group. 
20.9 
58.2 
73.1 
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Table 3. lncidences of General Symptoms in the First 48 Hours following Vaccination* 
Symptom 
(n =TS6j 
Vaccine Dose 
I /I !!/ Booster 
(n =B85j (n =TSf3j (n =B85j (n =T84) (n =B85) (n =T74j (n =B67, 
Fever (> 38°C) 3.5 1.2 3.5 2.4 2.4 
Loss of appetite 11.6 7.1 8.1 4.7 7.1 
Restlessness 5.8 8.2 10.5 11.8 6.0 
Unusual crying (> 1 h) 2.3 1.2 1.2 1.2 2.4 
Diarrhea 5.8 10.6 9.3 7.1 3.6 
Vomiting 8.1 5.9 8.1 5.9 3.6 
*As a aercentaae of total number of reooti sheets returned for each dose of tri- and bicomoonent DTaP administered. 
2.4 38.8 28.4 
7.1 14.9 6.0 
14.1 10.8 7.5 
1.2 0 1.5 
2.4 16.2 11.9 
4.7 2.7 3.0 
T = tricompon&t group; B = bicomponent group 
vaccination also led to significant increases in reports of within 48 hours of booster vaccination: one in group B 
fever (P c 0.001, see Table 3). The incidences of all other and two in group T All these reactions were transient 
systemic adverse reactions remained unchanged between and resolved spontaneously without sequleae. There were 
primary and booster vaccination. no other reports of severe general symptoms. 
Whereas during the primary vaccination course 
between 31% and 47% of the vaccine doses were not 
associated with adverse symptoms, only 17.6% and 10.4% 
of infants had no adverse symptoms after administration 
of the booster doses of tri- and bicomponent vaccines, 
respectively, with no significant difference between the 
two vaccines (Figure 1). 
Immunogenicity 
Only one severe adverse reaction was noted during 
the primary vaccination course: a child in group B expe- 
rienced severe redness and swelling (> 20 mm) on the 
second day after the second vaccination, which resolved 
spontaneously within 24 hours. Booster doses were fol- 
lowed by reports of redness and swelling beyond 20 mm 
in 15 (20.3%) and 13 (17.6%) of the 74 group T infants, 
respectively, and in 12 (17.9%) and 10 (14.9%) of the 67 
group B infants. In one group B case, local swelling was 
extensive enough to be reported as involving the whole 
thigh. There were three cases of severe fever (> 39.5”C) 
50 , 1 
Table 4 summarizes the serologic data for pertussis anti- 
bodies of the infants before and 1 month after primary 
and booster vaccination. Maternal anti-PT and antiper- 
tactin antibodies were observed in 9.5 to 17.5%, and 
maternal anti-FHA antibodies in 31 to 36% of infants prior 
to immunization. Whereas all initially seronegative chil- 
dren had seroconverted 1 month after the primary immu- 
nization (data not shown), a few initially seropositive 
children did not display a signitlcant increase in antibody 
titer. For PT antibodies, this occurred in 1 of 11 cases in 
group T and in 2 of 7 cases in group B; for FHA, in 3 of 
29 cases in group T and in 4 of 23 cases in group T; and 
for pertactin, in 1 of 14 cases in group T. However, each 
of these children displayed a positive seroresponse (dou- 
bling of antibodies) against at least one of the B.pertus- 
sis antigens in the vaccine. Approximately 1 month after 
the third dose, there were significant increases in anti- 
FHA antibody titers in 96.3%, and in anti-PT and antiper- 
tactin antibody titers in 98.8% of all the subjects in group 
T, and anti-PT (97.3%) and anti-FHA (94.6%) antibodies 
were induced in a similar manner in the bicomponent 
group. There were no signficant differences in the geo- 
metric mean titers for these antibodies between the two 
groups (Figure 2). 
40 
gT 
s 
8 30 
‘0 
8 
t 
g *O 
E 
E 
2 10 
0 
I II Ill I-III inc. Booster 
Vaccine dose 
Figure 1. Number of tricomponent (open columns) and bicompo- 
nent (filed columns) vaccine doses not associated with adverse symp- 
toms (% of administered doses) during the primary vaccinations 
separately (I, II, & Ill) and cumulatively (I-III), and the booster dose. 
Immediately before the booster vaccinations, the pat- 
tern of antipertussis antibodies had altered only slightly 
However, there was a small decrease in the prevalence 
of anti-PT antibodies in both groups (P c 0.001). The 
booster vaccination induced a significant rise in specific 
antibody titers in 97.9 to 100% of children who received 
the tricomponent vaccine with no significant differences 
between the three specific antigens. The immunogenicity 
of the bicomponent vaccine was almost identical, with 
increased anti-FHA and anti-PT antibodies in 98.1% and 
100% of infants, respectively Importantly, all the subjects 
who were seronegative prior to the booster vaccination 
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Table 4. Seropositive Status of the Infants and the Geometric Mean Titers with Respect to the Three Specified Pertussis Antigens before 
and after the Primary and Booster Vaccinations 
Sampling Point 
PT FHA Pertactin 
T B T B T B 
% GMT % GMT % GMT % GMT % GMT % GMT 
Preprimaty 13.8 3.1 9.5 2.8 36.3 4.0 31 .l 3.9 17.5 3.3 16.2 3.2 
Postprimafy 100.0 32.4 100.0 40.5 100.0 50.2 100.0 70.6 100.0 111.0 2.7 2.6 
Prebooster 81.3 10.2 81.8 12.0 100.0 39.3 100.0 36.7 91.7 20.6 5.5 2.8 
Postbooster 100.0 115.0 100.0 167.0 100.0 514.0 100.0 692.0 100.0 633.0 7.3 2.6 
PT = pertussis toxoid; FHA = filamentous hemaggiutinin; T = tricomponent group; 6 = bicomponent group; GMT = geometric mean titers (N/ml). 
demonstrated production of antibodies to the corre- 
sponding antigens after the booster. 
Three subjects vaccinated with the bicomponent vac- 
cine had positive pertactin antibody titers prior to the 
booster vaccination (6, 41, and 47 EL.U/mL, respectively). 
In two of these infants, antipertactin antibodies were not 
detectable after the booster vaccination. In addition, three 
subjects from this group with no antipertactin antibod- 
ies present before booster vaccination had detectable 
antibody titers against this antigen 4 to 8 weeks later 
(Table 4). The reason for the presence of antipertactin 
antibodies in subjects not vaccinated with this antigen is 
not known, but pertactin is not specific for B.pertussis, 
and natural exposure to B. pertussis could not be 
excluded. 
Both vaccines induced similar immune responses 
against tetanus and diphtheria toxoids (Table 5). All sub- 
jects had antibody titers in excess of 0.1 IU/mL 4 to 6 
weeks after the primary vaccination course. Before the 
booster dose, protective titers 0 0.1 IU/mL) were found 
in 93.7% of group T and in 96.4% of group B for antidiph- 
theria antibodies, and 79.2% and 87.3%, respectively, for 
antitetanus antibodies. When sampled after their respec- 
tive booster vaccinations, all subjects had antibody titers 
in excess of 0.1 IU/mL for both antigens. Indeed, all sub- 
jects had antidiphtheria titers in excess of 1 .O IU/mL, and 
97.9% of group T and 98.2% of the B group had anti- 
tetanus titers in excess of 1.0 IU/mL. 
DISCUSSION 
In many European countries, whooping cough is still 
one of the most frequent diseases of childhood. Although 
usually less than 5% of children with clinical pertussis 
need to be hospitalized, the disease does impose finan- 
cial and emotional strain and distress on affected fami- 
lies, and there is always the risk of severe complications. 
An effective vaccine with a high degree of acceptance 
by the medical community and the caretakers of chil- 
dren is the only means to increase vaccination coverage 
and hence lower the incidence and morbidity of B.per- 
tussis infection in the long term. However, local and/or 
systemic adverse reactions after immunization with the 
classic whole-cell vaccine occur in 50 to 90% of infants 
not previously immunized and an even higher percent- 
age experience adverse reactions after booster vaccina- 
tion.3,5,12,14,16,17,21 To overcome these constraints, various 
acellular pertussis vaccines are currently under clinical 
investigation as potential candidates to replace whole-cell 
vaccines.26 There is still some debate over how many 
antigenically defined components should be incorpo- 
rated in such a vaccine to combine maximal efficacy 
(i.e., a high protection rate) with a minimum of adverse 
reactions. 
The function of the individual components of B.per- 
tussis in the sequence of pathogenic events in humans is 
still far from being fully understood. Moreover, the role of 
the immune response to different antigenic components 
in prevention of colonization and disease remains poorly 
defined.*’ Four different types of antigens have been suf- 
ficiently well characterized to be included in a multicom- 
ponent pertussis vaccine: pertussis toxoid, filamentous 
hemagglutinins, a 69 kDa nonfimbrial outer membrane 
antigen (pertactin) and agglutinogens. Although for many 
years a major pathogenic role has been attributed to the 
PT antigen, a more recent investigation suggests that it 
plays only a minor role. ” Filamentous hemagglutinin is a 
nontoxoid molecule that plays a significant role in adher- 
ence of B.pertussis to endothelial cells, and which is able, 
like agglutinogens, to induce a protective immunity in ani- 
mal models as well as in human B.pertussis infection.29~30 
Antibodies against pertactin, an antigen responsible for 
the invasion of eukaryotic cells, have been demonstrated 
after an infection with B,pertussis as well as after active 
immunization with whole-cell vaccines.31,32 Analysis of the 
Japanese acellular vaccines has revealed that pertactin is 
Table 5. Pre- and PostvaccinaUon Antidiphtheria and Antitetanus 
Serologic Status 
Seropositivity 
Antidiphtheria Antitetanus 
T B T B 
%* GMT %* GMT %* GMT %* GMT 
Preprimaty 12.5 0.06 9.5 0.06 60.0 0.17 63.5 0.20 
Postprimaty 100.0 2.22 100.0 2.57 100.0 0.88 100.0 1.02 
Prebooster 93.7 0.65 96.4 0.61 79.2 0.18 87.3 0.23 
Postbooster lOO.O+ 17.61 100.0+19.30 100.0 5.15 100.0 6.85 
*Percentage of seropositive subjects (antibody titers > 0.1 k/ml). 
+ln all cases antibody titers were greater than 1 IU/mL. 
GMT = geometric mean titers (IU/mL). 
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Figure 2. Mean geometric mean titers (GMT) for each of the three 
pertussis antigens, PT, FHA, pertactin, at the four blood sampling points 
in tricomponent (open columns) and bicomponent (filled columns) 
groups. Bars represent the 95% confidence limits. 
a previously unidentified component of some of these 
vaccines31 
To investigate the suitability of inclusion of pertactin 
in an acellular pertussis vaccine, a prospective, randomized, 
double-blind study was conducted with a bicomponent 
and a tricomponent DTaP vaccine in children undergo- 
ing primary and booster vaccination. The results show 
that between 31% and 47% of recipients of the vaccines 
remained without symptoms after each of the doses of 
the primary immunization course, and that approximately 
10% suffered no adverse reactions, irrespective of which 
vaccine was administered. The most commonly observed 
adverse reactions were local redness and swelling, and 
transient diarrhea. With few exceptions, all adverse reac- 
tions occurred within 48 hours after vaccination and did 
not necessitate any specific medication. In all but three 
cases of fever and one of extensive redness and swelling, 
local and systemic adverse reactions were reported as 
mild or moderate. These figures sustain the observations 
made in small-scale studies using a bicomponent and a 
large multicenter study performed with the tricompo- 
nent vaccine.‘*J9 Thus, it appears that the incidence and 
severity of adverse reactions induced by DTaP vaccines 
during primary immunization is not necessarily associ- 
ated with the number of antigen components present in 
the vaccine. A similar conclusion was drawn from the 
comparison of the reactogenicities of nine mono-, bi-, 
and tricomponent DTaP vaccines given as booster immu- 
nizations.33 
It is a common feature of pertussis vaccines that 
booster immunization in 18- to 25-month-old children 
elicits more frequent and more intense adverse reactions 
than does primary immunization of infants.13 In the pre- 
sent study, the incidences of local redness, swelling and 
pain, as well as of fever and diarrhea, were also markedly 
higher following the booster vaccination, when com- 
pared with the third dose of the primary vaccination. 
This was accompanied by significant increases in the 
number of local reactions (redness, swelling) reported 
as severe (diameter > 20 mm), but not in severe systemic 
reactions after booster vaccination. However, the inci- 
dence rates and severity of adverse reactions remained 
within the range known from previous studies in chil- 
dren who were initially vaccinated with the classic whole- 
cell vaccine and then boostered with an acellular 
bicomponent or tricomponent vaccine.12-17,21 More impor- 
tantly, all the adverse reactions were transient and 
resolved spontaneously without sequelae. The increase in 
frequency and severity of adverse reactions was almost 
identical in the bicomponent and the tricomponent 
vaccine groups. Despite the increased incidences of local 
and general adverse reactions after booster vaccination in 
the authors’ studies, they are still lower than those 
observed following the administration of a fourth dose of 
whole-cell DTP vaccines.12.13-15,18,19,z6 
After a complete primary immunization course with 
the bicomponent or tricomponent vaccine, all initially 
seronegative children produced antibodies to the two or 
three corresponding antigens. Furthermore, there were 
significant seroresponses against at least one of the antigen 
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components in 71 to 93% of children who were seroposi- 
tive at admission to the study Combining seronegative and 
seropositive subjects, in group B, a significant antibody 
response was elicited in 97.3% against PT and in 94.6% 
against FHA, and in group T a significant antibody response 
was elicited in 98.8% against PT, in 96.3% against FHA, and 
in 98.8% against pertactin, with all children having anti- 
bodies against each of the pertussis vaccine components. 
Thus, this study confirms the excellent immunogenicity of 
acellular bicomponent and tricomponent vaccines, as pre- 
viously demonstrated in comparative studies.12~16-19~26 
The superior ability of the acellular vaccines to gen- 
erate an immune response to defined B.pertussis antigens 
in comparison with whole-cell vaccine was also evident 
after booster immunization. One month after the booster 
there were significant increases in antibody titers against 
all three antigens in 97.9 to 100% of group T children, 
and against PT and FHA in 98.1 to 100% of group B chil- 
dren. Conventional whole-cell vaccines induce a signifi- 
cant immune response in only 64 to 90% of children 
receiving a booster vaccination.6~7,12~16 In studies in which 
GMTs rather than seroconversion rates were assessed, 
the superior immunogenicity of the acellular vaccine was 
also a consistent finding.13~24 
In a major clinical trial in the United States, 13 dif- 
ferent acellular pertussis vaccines, including the two pre- 
sented in this study, were compared for their 
immunogenic&y and reactogenicity in a three-dose pri- 
mary course in infants at 2, 4, and 6 months of age.z6 The 
conclusions from that trial were similar to those of the pre- 
sent study in that acellular pertussis vaccines were 
markedly less reactogenic than whole-cell vaccines with- 
out sacrificing immunogenic&y. However, the results 
obtained with the same two vaccines used in the present 
study were different in that the tricomponent induced a 
significantly lower immune response to pertussis toxoid 
than bicomponent vaccine, with seroconversion rates of 
70.8% and 90.3%, respectively. As this was not the case 
in the present study, the authors are unable to explain 
the difference in these results. Although different lots of 
vaccine were used in the two studies, other trials have 
demonstrated good lot-to-lot consistency in the immuno- 
genic properties of the tricomponent vaccine.34 
Since, at present, the exact pattern of antibody idio- 
types and of cellular immune effector mechanisms that 
confer protection against B.pertussis is not known, the 
best means of measuring vaccine efficacy is the failure to 
develop clinically overt whooping cough after contact 
with diseased individuals. A recent household contact 
study demonstrated a vaccine efficacy of 89% against cul- 
ture-confirmed illness with cough for more than 21 days 
following a three-dose primary vaccination with the same 
tricomponent vaccine as used in the present report.35 The 
protection was maintained until at least the time for the 
booster dose. In the same study, a whole-cell vaccine had 
an efficacy rate of 98%. A study in Italy reported efficacies 
of 84% for the tricomponent vaccine described in this 
report and for a similar tricomponent acellular vaccine 
containing a genetically detoxified pertussis toxin (Chi- 
ron Biocine, Sienna, Italy), compared with an efficacy of 
only 36% for a whole-cell vaccine.36 A study in Sweden 
reported an efficacy of 58.9% for the same bicomponent 
vaccine as used in the present study, compared with effi- 
cacies of 85.2% and 48.3% for a five-component (PT, FHA, 
pertactin, and fimbriae 2 and 3) acellular pertussis vaccine 
and a whole-cell vaccine respectively3’ When vaccine eff- 
cacy was determined in another large trial in Sweden, an 
acellular bicomponent vaccine containing PT and FHA 
from another manufacturer showed a protection level of 
89 to 92%,38 and a study in Japan using a tricomponent 
vaccine with PT, FHA, and pertactin demonstrated an even 
higher protection level of 98%.39 The comparison of the 
data from the various studies is curtailed by different 
methodologic approaches and the use of vaccines with 
varying contents of defined antigensz7 and the variation 
in reported efficacy rates for different whole-cell vaccines 
already has been noted. *O However, despite these dis- 
crepancies, it seems clear that the protection rates of acel- 
lular vaccines are at least as high as those provided by 
classic whole-cell vaccines. The differences between 
two-, three-, and five-component acellular vaccines are 
less clear, although the Italian and Swedish studies suggest 
that efficacy is improved by the inclusion of pertactin, 
whereas additional antigens do not seem to bring any 
further benefit.36,37 
In the current study, the bicomponent and the tri- 
component vaccines were of similar reactogenicity and 
induced an almost identical immune response to the cor- 
responding antigens. Therefore, administration of the tri- 
component vaccine for primary and booster vaccination 
may have advantages, because this vaccine generates a reli- 
able response to an additional antigen that has been impli- 
cated in immunoprotection against B. petiussis. 
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